Effects of topical tranilast on corneal haze after photorefractive keratectomy.
OBJECTIVE
To determine whether topical tranilast might reduce corneal haze through suppression of transforming growth factor (TGF)-beta1 synthesis in keratocyte after photorefractive keratectomy.


METHODS
Department of Ophthalmology, Korea University College of Medicine, Seoul, Republic of Korea.


METHODS
Photorefractive keratectomy was performed on 48 eyes of 28 white rabbits and 24 eyes in a tranilast group were treated with tranilast solution, and the other 24 eyes in control group were treated with saline after laser ablation. The grades of corneal haze at 1, 2, 4, and 8 weeks after surgery were evaluated in 10 eyes of each group for comparison. Immunohistochemistry was performed on 10 eyes of each group, and Western blot analysis was done on 4 eyes of each group for studying TGF-beta1 expression at postoperative day 7.


RESULTS
There was no statistically significant difference in corneal haze between 2 groups from week 1 to week 4 after surgery, but a significant difference was found at week 8 after photorefractive keratectomy (P=.02). The mean number of keratocytes that expressed TGF-beta1 in the tranilast group was 58.3 (+/-17.2), which showed significant difference, compared with that of the control group, 104.5 (+/-23.0) (P<.01). Western blot analysis also revealed that the amount of TGF-beta1 in tranilast group was slightly less than the control group.


CONCLUSIONS
Topical tranilast could reduce corneal haze by suppressing TGF-beta1 expression in keratocytes after photorefractive keratectomy.
Song
Jong-Suk
JS
Department of Ophthalmology, Gil Medical Center, Gachon Medical School, Incheon, Republic of Korea.
Jung
Hai Ryun
HR
Kim
Hyo-Myung
HM
D000287:Administration, Topical; D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D003315:Cornea / Q000187:drug effects / Q000378:metabolism; D003318:Corneal Opacity / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D007124:Immunoenzyme Techniques; D054018:Lasers, Excimer; D009883:Ophthalmic Solutions / Q000494:pharmacology*; D018903:Photorefractive Keratectomy / Q000009:adverse effects*; D011817:Rabbits; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053773:Transforming Growth Factor beta1; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D018926:Anti-Allergic Agents; D009883:Ophthalmic Solutions; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D062367:ortho-Aminobenzoates; C012293:tranilast